Moderna and Merck report #cancervaccine progress data. What does this mean for #pediatriccancers? #StJude immunologist Dr. Paul Thomas: “We know pediatric tumors elicit immune responses, but we aren't as good at enlisting those responses to destroy the tumor as we are in some adult cancers. We should turn to understanding what vaccine features, and the elicited responses, drive the observed efficacy and determine whether we can create these responses in lower mutation-burden pediatric tumors.”